AAPL   318.35 (+0.03%)
FB   227.22 (+0.78%)
GOOGL   1,428.35 (+0.71%)
AMZN   2,422.41 (+0.89%)
NVDA   344.84 (+1.58%)
CGC   17.86 (-17.77%)
MU   46.72 (+0.54%)
GE   6.65 (-2.06%)
TSLA   811.48 (+0.70%)
AMD   52.51 (+1.49%)
ACB   14.27 (-6.98%)
GILD   75.25 (-0.09%)
DIS   116.37 (-0.33%)
BA   146.48 (-2.23%)
AAPL   318.35 (+0.03%)
FB   227.22 (+0.78%)
GOOGL   1,428.35 (+0.71%)
AMZN   2,422.41 (+0.89%)
NVDA   344.84 (+1.58%)
CGC   17.86 (-17.77%)
MU   46.72 (+0.54%)
GE   6.65 (-2.06%)
TSLA   811.48 (+0.70%)
AMD   52.51 (+1.49%)
ACB   14.27 (-6.98%)
GILD   75.25 (-0.09%)
DIS   116.37 (-0.33%)
BA   146.48 (-2.23%)
AAPL   318.35 (+0.03%)
FB   227.22 (+0.78%)
GOOGL   1,428.35 (+0.71%)
AMZN   2,422.41 (+0.89%)
NVDA   344.84 (+1.58%)
CGC   17.86 (-17.77%)
MU   46.72 (+0.54%)
GE   6.65 (-2.06%)
TSLA   811.48 (+0.70%)
AMD   52.51 (+1.49%)
ACB   14.27 (-6.98%)
GILD   75.25 (-0.09%)
DIS   116.37 (-0.33%)
BA   146.48 (-2.23%)
AAPL   318.35 (+0.03%)
FB   227.22 (+0.78%)
GOOGL   1,428.35 (+0.71%)
AMZN   2,422.41 (+0.89%)
NVDA   344.84 (+1.58%)
CGC   17.86 (-17.77%)
MU   46.72 (+0.54%)
GE   6.65 (-2.06%)
TSLA   811.48 (+0.70%)
AMD   52.51 (+1.49%)
ACB   14.27 (-6.98%)
GILD   75.25 (-0.09%)
DIS   116.37 (-0.33%)
BA   146.48 (-2.23%)
Log in

ETR:SAZSTADA Arzneimit/AKT o.N. Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume92,068 shs
Average Volume51,761 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxone for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Pantoprazole for gastric ulcer/reflux. The Branded Products segment offers APO-Go a Parkinson's medicine; Grippostad a cold medicine; Aqualor for rhinitis/sore throat; Snup for rhinitis; and Vitaprost for prostate disease indications. The company is also involved in the wholesale activities in the pharmaceutical market. It serves patients and consumers, doctors, pharmacies and pharmacy chains, hospitals, mail-order companies, buying groups, wholesalers, and other service providers in the health care market, as well as public or private health insurance organizations. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare Holding GmbH.
Read More
STADA Arzneimit/AKT o.N. logo

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.38 out of 5 stars


Industry, Sector and Symbol

Stock Exchange ETR
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolETR:SAZ
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.stada.de
Phone+49-6101-6030

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable
SAZ Rates by TradingView

Receive SAZ News and Ratings via Email

Sign-up to receive the latest news and ratings for SAZ and its competitors with MarketBeat's FREE daily newsletter.

STADA Arzneimit/AKT o.N. (ETR:SAZ) Frequently Asked Questions

Has STADA Arzneimit/AKT o.N. been receiving favorable news coverage?

Media coverage about SAZ stock has been trending extremely negative on Friday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. STADA Arzneimit/AKT o.N. earned a media sentiment score of -4.8 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutSTADA Arzneimit/AKT o.N..

Who are some of STADA Arzneimit/AKT o.N.'s key competitors?

What other stocks do shareholders of STADA Arzneimit/AKT o.N. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other STADA Arzneimit/AKT o.N. investors own include Prosiebensat 1 Media (PSM), Renault (RNO), VOLKSWAGEN (VLKAY), Volkswagen (VOW3), Andersons (ANDE), Hikma Pharmaceuticals (HIK), Opko Health (OPK), Sarepta Therapeutics (SRPT), Adaptimmune Therapeutics (ADAP) and AcelRx Pharmaceuticals (ACRX).

Who are STADA Arzneimit/AKT o.N.'s key executives?

STADA Arzneimit/AKT o.N.'s management team includes the following people:
  • Mr. Mark Burgess Keatley MBA, MA, MPhil, CFO & Member of Exec. Board (Age 61)
  • Mr. Peter Goldschmidt, Chairman of the Exec. Board & CEO (Age 54)
  • Mr. Miguel Pagan Fernandez, CTO & Member of Exec. Board (Age 53)
  • Mr. Sebastian Kramer-Bach, Exec. VP of Corp. Communication (Age 43)
  • Ms. Kay Reubelt, Director of Investor Relations

What is STADA Arzneimit/AKT o.N.'s stock symbol?

STADA Arzneimit/AKT o.N. trades on the ETR under the ticker symbol "SAZ."

What is STADA Arzneimit/AKT o.N.'s official website?

The official website for STADA Arzneimit/AKT o.N. is www.stada.de.

How can I contact STADA Arzneimit/AKT o.N.?

STADA Arzneimit/AKT o.N.'s mailing address is Stadastrasse 2-18, BAD VILBEL, 61118, Germany. The company can be reached via phone at +49-6101-6030.

This page was last updated on 5/29/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.